177Lu Dotatate (Lutathera) is a radiolabeled somatostatin analog peptide approved by the FDA for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. Specifically, it is indicated for:
- Treatment of somatostatin receptor-positive GEP-NETs including foregut, midgut, and hindgut neuroendocrine tumors
- Treatment of well or moderately differentiated, locally advanced or metastatic GEP-NETs
- Treatment of patients with progressive, well differentiated metastatic midgut NETs whose disease has progressed within the last 6 months
Key features of 177Lu Dotatate therapy:
- It binds to somatostatin receptors (particularly sst2 receptors) which are expressed in high density on neuroendocrine tumor cells
- Once bound, it internalizes into tumor cells and the 177Lu radiolabel irradiates the cells
- This makes it an excellent targeted radionuclide therapy option for advanced GEP-NETs
The approval of 177Lu Dotatate was based on the results of the
NETTER-1 phase 3 trial, which demonstrated:
- Improved progression-free survival compared to high-dose octreotide LAR (a non-radiolabeled somatostatin analog) in patients with advanced midgut NETs
- An overall response rate of 18% per RECIST 1.1 criteria
- Limited grade 3/4 hematological toxicity (primarily lymphopenia)
177Lu Dotatate represents an important step forward in the treatment paradigm for advanced GEP-NETs. At Hormone Health Institute, we specialize in comprehensive, integrated care for patients with
neuroendocrine disorders including NETs and carcinoid syndrome. Our care team has extensive expertise in:
- Accurate diagnosis and staging
- Sequence and combination of therapeutic modalities like surgery, SSA therapy, PRRT, TAE/TACE, molecularly targeted treatments
- Optimal supportive care with a patient-centric approach
We offer
state-of-the-art 177Lu Dotatate PRRT as part of our integrated NET program.
Contact us to learn more about our clinical trials and the latest advancements in NET treatments.
